Logo

American Heart Association

  14
  0


Final ID: MP789

Refining Prediction of Cerebrovascular Events in ATTR-CM with Sinus Rhythm to Guide Preventive Anticoagulation

Abstract Body (Do not enter title and authors here): Background: Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) face a significant risk of cerebrovascular events, even when in sinus rhythm (SR). However, no validated tool exists to identify those at highest risk.
Hypothesis: Atrial amyloid infiltration may cause loss of effective left atrial (LA) contraction despite SR, a phenomenon termed atrial electromechanical dissociation (AEMD). We postulate that LA dysfunction, particularly AEMD, increases the risk of cerebrovascular events and could guide preventive anticoagulation at individual level.
Aims: To (i) characterize the LA phenotype using speckle-tracking strain analysis, (ii) assess the potential association of LA function with stroke or TIA, and (iii) develop an algorithm to predict 1-year risk of cerebrovascular events in patients with SR.
Methods: Retrospective analysis of patients diagnosed with ATTR-CM (Jan 2003–Dec 2023) at the UK National Amyloidosis Centre. LA function was assessed by speckle-tracking analysis. AEMD was defined as SR with absent LA strain contraction. The primary outcome was time to either stroke or TIA. The secondary outcome was AF development.
Results: Among 2310 ATTR-CM patients (74.5% wild-type),116(5.0%) had AEMD,757(32.8%) had SR with LA contraction and 1437(62.2%) had AF on anticoagulation. Over 34[IQR18–54] months,5.0%(n=114) patients experienced the composite outcome of stroke/TIA and 30.9%(n=270/874 in SR) developed AF. AEMD was associated with an increased risk of stroke/TIA compared to SR with LA contraction (HR:3.10,95%CI1.95-4.96;p<0.001) and to AF on anticoagulation (HR:10.62,95%CI6.21-18.16;p<0.001)(Fig 1). AEMD also conferred greater risk of AF development(HR:2.40,95%CI1.80–3.19,p<0.001)(Fig 1). These finding were consistent across the 3 main genotypes (wild-type, T60A and V122I), the 3 NAC disease stages and disease-modifying treatment/enrolment in clinical trials.
A flowchart for predicting 1-year risk of stroke/TIA was developed combining transmitral A wave and LA contraction. A-wave ≥90 cm/s ruled out stroke/TIA with sensitivity 96.6% and NPV 98.7%. In patients with A-wave <90 cm/s, worse LA contraction was associatied to a higher risk of stroke/TIA(HR1.28,95%CI1.10–1.50,p=0.001). Risk increased stepwise, peaking in AEMD (9.5 events/100 pt-years)(Tab 1).
Conclusion: LA dysfunction, especially AEMD, confers greater risk of stroke/TIA and AF risk in ATTR-CM patients. AEMD may identify high-risk patients who could benefit from preventive anticoagulation.
  • Porcari, Aldostefano  ( Royal Free Hospital , London , United Kingdom )
  • Solomon, Scott  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Martinez-naharro, Ana  ( Royal Free Hospital , London , United Kingdom )
  • Hawkins, Philip  ( National Amyloidosis Centre , London , United Kingdom )
  • Gillmore, Julian  ( National Amyloid Centre , London , United Kingdom )
  • Fontana, Marianna  ( National Amyloid Centre , London , United Kingdom )
  • Dal Passo, Beatrice  ( Department of Cardiology, Azienda Ospedaliero Universitaria di Ferrara , Ferrara , Italy )
  • Venneri, Lucia  ( Royal Free Hospital , London , United Kingdom )
  • Bandera, Francesco  ( IRCCS POLICLINICO SAN DONATO , San Donato Milanese , Italy )
  • Razvi, Yousuf  ( Royal Free Hospital , London , United Kingdom )
  • Sheikh, Awais  ( National Amyloid Centre , London , United Kingdom )
  • Mansell, Josephine  ( National Amyloid Centre , London , United Kingdom )
  • Zaro, Elisa  ( University of Trieste , Trieste , Italy )
  • Giampieri, Gaia  ( National Amyloid Centre , London , United Kingdom )
  • Author Disclosures:
    Aldostefano Porcari: DO have relevant financial relationships ; Speaker:Alnylam:Past (completed) | Scott Solomon: DO have relevant financial relationships ; Research Funding (PI or named investigator):Alexion, Alnylam, Applied Therapeutics, AstraZeneca, Bellerophon, Bayer, BMS, Boston Scientific, Cytokinetics, Edgewise, Eidos/BridgeBio, Gossamer, GSK, Ionis, Lilly,NIH/NHLBI, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Tenaya, Theracos, US2.AI:Active (exists now) ; Consultant:Abbott, Action, Akros, Alexion, Alnylam, Amgen, Arena, Askbio, AstraZeneca, Bayer, BMS, Cardior, Cardurion, Corvia, Cytokinetics, GSK, Intellia, Lilly, Novartis, Roche, Theracos, Quantum Genomics, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, Valo, Synhale, Recordati:Active (exists now) | Ana Martinez-Naharro: DO NOT have relevant financial relationships | Philip Hawkins: DO NOT have relevant financial relationships | Julian Gillmore: No Answer | Marianna Fontana: DO have relevant financial relationships ; Consultant:Alnylam, Alexion/Caelum Biosciences, Astrazeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Prothena, Pfizer, Novonordisk, Bayer, Mycardium:Active (exists now) ; Individual Stocks/Stock Options:Mycardium (shares):Active (exists now) ; Individual Stocks/Stock Options:LexeoTherapeutics (share options):Active (exists now) ; Other (please indicate in the box next to the company name):Alnylam, Bridgbio, Astrazeneca, Pfizer.(research grants):Active (exists now) | Beatrice Dal Passo: DO NOT have relevant financial relationships | Lucia Venneri: No Answer | Francesco Bandera: No Answer | Yousuf Razvi: DO NOT have relevant financial relationships | Awais Sheikh: DO NOT have relevant financial relationships | Josephine mansell: No Answer | Elisa Zaro: No Answer | Gaia Giampieri: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Under the Sheets: Contemporary Cardiac Amyloidosis Research

Saturday, 11/08/2025 , 09:15AM - 10:25AM

Moderated Digital Poster Session

More abstracts on this topic:
More abstracts from these authors:
Mapping the Myocardial Amyloid Burden in Transthyretin Cardiomyopathy: A Large-Scale Study Using Cardiac Magnetic Resonance and Extracellular Volume in 1,400 Patients

Sheikh Awais, Knight Daniel, Virsinskaite Ruta, Kotecha Tushar, Lachmann Helen, Wechalekar Ashutosh, Gillmore Julian, Fontana Marianna, Achten Anouk, Razvi Yousuf, Porcari Aldostefano, Mansell Josephine, Venneri Lucia, Martinez-naharro Ana, Whelan Carol, Hawkins Philip

Effects of Vutrisiran on Measures of Cardiac Structure, Function and Amyloid Burden by Cardiovascular Magnetic Resonance from the HELIOS-B Trial

Razvi Yousuf, Bansilal Sameer, Eraly Satish, Aldinc Emre, Solomon Scott, Gillmore Julian, Fontana Marianna, Sheikh Awais, Patel Rishi, Achten Anouk, Mansell Josephine, Martinez-naharro Ana, Venneri Lucia, Hawkins Philip, Vest John

You have to be authorized to contact abstract author. Please, Login
Not Available